LADX Stock Overview

A biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. More details

LADX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($832K)

Has less than 1 year of cash runway

Negative shareholders equity

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

LadRx Corporation Competitors

SQZ Biotechnologies

OTCPK:SQZB

US$884.7k

Revelation Biosciences

NasdaqCM:REVB

US$1.5m

Scorpius Holdings

NYSEAM:SCPX

US$1.4m

Windtree Therapeutics

NasdaqCM:WINT

US$1.3m

Price History & Performance

Summary of share price highs, lows and changes for LadRx
Historical stock prices
Current Share Price	US$1.75
52 Week High	US$3.50
52 Week Low	US$0.46
Beta	0.92
1 Month Change	4.17%
3 Month Change	1.16%
1 Year Change	9.38%
3 Year Change	-96.57%
5 Year Change	-97.50%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	LADX	US Biotechs	US Market
7D	2.9%	1.7%	-0.8%
1Y	9.4%	-3.1%	25.2%

Return vs Industry: LADX exceeded the US Biotechs industry which returned -3.1% over the past year.

Return vs Market: LADX underperformed the US Market which returned 25.2% over the past year.

Price Volatility

Is LADX's price volatile compared to industry and market?
LADX volatility
LADX Average Weekly Movement	66.3%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.3%

Stable Share Price: LADX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LADX's weekly volatility has increased from 39% to 66% over the past year.

About the Company

Founded	Employees	CEO	Website
1985	2	Stephen Snowdy	www.ladrxcorp.com

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent which targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer.

LadRx Corporation Fundamentals Summary

How do LadRx's earnings and revenue compare to its market cap?
LADX fundamental statistics
Market cap	US$831.75k
Earnings (TTM)	-US$2.78m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Is LADX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LADX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$2.78m
Earnings	-US$2.78m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-5.61
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did LADX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/30 02:04
End of Day Share Price	2025/01/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LadRx Corporation is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ashok Kumar	Aegis Capital Corporation
Jonathan Aschoff	Brean Capital
Christopher James	FBR Capital Markets & Co.